Surrogate Endpoints for Overall Survival in Advanced Hepatocelluar Carcinoma in the Era of Immunotherapy: A Trial Level Meta-Analysis
The correlation between HR-PFS and HR-OS is weak in 1st-line RCTs in advanced HCC where OS remains the most appropriate endpoint. There is a strong association between HR-PFS and HR-OS for 2nd-line RCTs, suggesting that PFS is a suitable surrogate endpoint in that setting.
Authors
- Rachel Goodwin (ORCID: https://orcid.org/0000-0002-0250-8479)
- Abdul Rehman Farooq (ORCID: https://orcid.org/0000-0001-5433-6245)
- Yacob Saleh (ORCID: https://orcid.org/0000-0001-6698-0919)
- Zeynep Baskurt (ORCID: https://orcid.org/0000-0002-0714-7406)
- Grainne O ́Kane
- Eric X. Chen (ORCID: https://orcid.org/0000-0002-4581-8848)
- Jennifer J. Knox (ORCID: https://orcid.org/0000-0003-3474-6647)
Institutions
- Ottawa Hospital (CA)
- Princess Margaret Cancer Centre (CA)
Publication Details
- Journal
- Liver Cancer
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1159/000548606
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00